Drug analysis: Opdivo

  • ID: 4462144
  • Drug Pipelines
  • 103 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells. PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Opdivo: Colorectal cancer (CRC)
Opdivo: Head and neck cancer
Opdivo: Hepatocellular carcinoma (HCC)
Opdivo: Bladder cancer
Opdivo: Glioblastoma (GBM)
Opdivo: Renal cell cancer (RCC)
Opdivo: Non-small cell lung cancer (NSCLC)
Opdivo: Gastric cancer
Opdivo: Melanoma

List of Figures
Figure 1: Opdivo for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Opdivo for colorectal cancer
Figure 3: Drug assessment summary of Opdivo for colorectal cancer
Figure 4: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016-25
Figure 5: Opdivo for head and neck cancer - SWOT analysis
Figure 6: Drug assessment summary of Opdivo for SCCHN
Figure 7: Drug assessment summary of Opdivo for SCCHN
Figure 8: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 9: Opdivo for HCC - SWOT analysis
Figure 10: Drug assessment summary of Opdivo for HCC
Figure 11: Drug assessment summary of Opdivo for hepatocellular carcinoma
Figure 12: Opdivo for urothelial bladder cancer - SWOT analysis
Figure 13: Drug assessment summary for Opdivo in urothelial bladder cancer
Figure 14: Drug assessment summary for Opdivo in urothelial bladder cancer
Figure 15: Opdivo for glioblastoma - SWOT analysis
Figure 16: Drug assessment summary for Opdivo in glioblastoma
Figure 17: Drug assessment summary for Opdivo in glioblastoma
Figure 18: Opdivo pivotal trial data in renal cell cancer
Figure 19: Opdivo for renal cell cancer - SWOT analysis
Figure 20: Drug assessment summary of Opdivo for renal cell cancer
Figure 21: Drug assessment summary of Opdivo for renal cell cancer
Figure 22: Opdivo for non-small cell lung cancer - SWOT analysis
Figure 23: Drug assessment summary for Opdivo in non-small cell lung cancer
Figure 24: Drug assessment summary for Opdivo in non-small cell lung cancer
Figure 25: Opdivo for gastric cancer - SWOT analysis
Figure 26: Drug assessment summary for Opdivo in gastric cancer
Figure 27: Drug assessment summary for Opdivo in gastric cancer
Figure 28: Opdivo in melanoma - SWOT analysis
Figure 29: Drug assessment summary of Opdivo for melanoma
Figure 30: Drug assessment summary of Opdivo for melanoma

List of Tables
Table 1: Opdivo drug profile
Table 2: Opdivo pivotal trial data in colorectal cancer
Table 3: Opdivo early-phase trials in colorectal cancer
Table 4: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Opdivo across the US and five major EU markets, by country, 2016-25
Table 6: Opdivo drug profile
Table 7: Opdivo pivotal trial data in head and neck cancer
Table 8: Opdivo ongoing late-phase trials in head and neck cancer
Table 9: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 10: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 11: Opdivo drug profile
Table 12: Opdivo Phase III trial in HCC
Table 13: Opdivo Phase I/II data in HCC
Table 14: Opdivo drug profile
Table 15: Opdivo pivotal trial data in urothelial bladder cancer
Table 16: Opdivo ongoing late-phase trials in urothelial bladder cancer
Table 17: Opdivo drug profile
Table 18: Opdivo Phase III data in glioblastoma
Table 19: Opdivo Phase III trials in glioblastoma
Table 20: Opdivo drug profile
Table 21: Opdivo ongoing Phase III clinical trial in renal cell cancer
Table 22: Opdivo drug profile
Table 23: Opdivo pivotal trial data in non-small cell lung cancer
Table 24: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
Table 25: Opdivo drug profile
Table 26: Opdivo late-phase trial in gastric cancer
Table 27: Opdivo early-phase data in gastric cancer
Table 28: Opdivo drug profile
Table 29: Opdivo pivotal trial data in melanoma
Table 30: Opdivo late-phase clinical trial data in melanoma
Table 31: Opdivo ongoing late-phase clinical trials in melanoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll